CNBC2020 Disruptor 50May 06, 2020Media CoverageRelated contentTempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGsTempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic ApplicationsTempus Reports Second Quarter 2026 Results